Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Authors: Henning Gruell, MD, Jesper D Gunst, MD, Yehuda Z Cohen, MD, Marie H Pahus, Jakob J Malin, MD, Martin Platten, MD, Katrina G Millard, RN, Martin Tolstrup, PhD, R Brad Jones, PhD, Winnifer D Conce Alberto, Julio C C Lorenzi, PhD, Thiago Y Oliveira, PhD, Tim Kümmerle, MD, Isabelle Suárez, MD, Cecilia Unson-O'Brien, PhD, Lilian Nogueira, PhD, Rikke Olesen, PhD, Lars Østergaard, ProfMD, Henrik Nielsen, ProfMD, Clara Lehmann, MD, Michel C Nussenzweig, ProfMD, Gerd Fätkenheuer, ProfMD, Florian Klein, ProfMD, Marina Caskey, ProfMD, Ole S Søgaard, ProfMD

Source: The Lancet Microbe, Vol 3, Iss 3, Pp e203-e214 (2022)

Subject Terms: Medicine (General), R5-920, Microbiology, QR1-502

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666524721002391; https://doaj.org/toc/2666-5247

Access URL: https://doaj.org/article/b572a4bc81f74c27b4e7e697acac132e